SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing significant intraday volatility following a strong fiscal first-quarter earnings report, with the community divided between long-term bullish sentiment regarding the company's cloud infrastructure backlog and frustration over perceived market maker manipulation. While many traders see the pullbacks as a "shakeout" or options-related noise, others cite concerns over debt levels and negative free cash flow as justification for the price weakness.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo shares are facing downward pressure following the announcement of a new $1 billion at-the-market equity offering program, which has triggered widespread concerns among traders regarding potential dilution. While the community remains deeply divided between long-term investors focused on the company's nuclear energy pipeline and short-term traders reacting to persistent insider selling and lack of immediate revenue, many are closely monitoring critical support levels.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is experiencing significant downward pressure following a UBS downgrade to 'Sell' with a slashed price target, as analysts and traders cite concerns over long build timelines, cash burn, and the lack of firm commercial commitments. While some market participants remain optimistic about the company's long-term potential in the nuclear energy sector, others are increasingly critical of the firm's minimal revenue and execution risks.

Alliance Entertainment Holding Corp. engages in the distribution of music, movies, and consumer electronics. It distributes its physical media, entertainment products, hardware, and accessories through an established multi-channel strategy. The company was founded in 1990 and is headquartered in Plantation, FL.

Alliance Entertainment Holding Corporation - Ordinary Shares - Class A

AENT is trending as traders analyze the company's recent earnings beat, with discussion focused on the potential for a rebound driven by its low float and exclusive physical media distribution partnerships. While some community members are optimistic about institutional support and growth opportunities in collectibles, others express skepticism regarding insider activity and the sustainability of recent price volatility.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell shares are trending following the company's strong fiscal quarterly results, which featured robust AI server demand and a massive order backlog, leading to upward price target revisions from analysts. While bullish traders emphasize the company's leadership in the AI infrastructure buildout and new S&P 100 inclusion, bearish sentiment is fueled by concerns over heavy insider selling, large debt offerings, and skepticism regarding the sustainability of the AI-driven valuation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as traders speculate on the timing and results of upcoming maintenance study data for its obesity candidate, VK2735. While some investors remain optimistic about potential buyout interest and the drug's efficacy, others express frustration over the company's communication style and lack of immediate news.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is trending due to anticipation of upcoming earnings on September 15th, with traders expressing strong bullish sentiment based on the company's role in the power infrastructure and data center buildout. While some participants express frustration over recent price volatility and insider selling, others highlight the company's significant backlog and electrification demand as indicators for long-term growth.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as traders debate the company's valuation and potential turnaround, with discussion focused on heavy insider buying and speculation regarding the possible sale of the STAR debit network. While some investors view the current price as a long-term value opportunity, others express significant frustration over management execution and weak performance, maintaining a bearish outlook until there is clear evidence of a recovery.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing significant selling pressure and negative sentiment following the release of Phase 3 IZAR-1 trial data, which traders viewed as failing to demonstrate a clear best-in-class efficacy profile, alongside the filing of a mixed shelf offering. Community discussion is heavily divided between those who remain optimistic about the company's long-term potential in hidradenitis suppurativa and those expressing frustration with management's communication, perceived lack of transparency, and dilution risks.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors react to a positive quarterly earnings report, with community members highlighting strong profitability, institutional confidence, and operational leverage. While some traders express frustration with the stock's volatility and the impact of broader macro headwinds, others remain bullish on the long-term potential for a valuation re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. "During the second quarter we continued to execute...

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?

Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential...

Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's  What You Should Know

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why You Should Add JANX Stock to Your Portfolio Now

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of +21.83% and -75.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter...

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Janux Therapeutics (NASDAQ:JANX) Upgraded by Truist Financial to Strong-Buy Rating

Truist Financial upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Monday...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

Equity

Bullish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.47	--	--	N/A
Q2 '26	-$0.25	-$0.35	-39.28%	MISSED
Q1 '26	-$0.55	-$0.39	29.16%	BEAT
Q4 '25	-$0.62	-$0.51	18.38%	BEAT
Q3 '25	-$0.61	-$0.39	36.32%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

JANX Earnings

Upcoming Earnings: Q3 '26

Historical Earnings